Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

[1]  S. Peters,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Alva,et al.  NB-UVB phototherapy in the treatment of anti-PD-1 inhibitor induced psoriasis: A case report , 2020 .

[3]  M. Hudson,et al.  Moving towards personalized treatments of immune-related adverse events , 2020, Nature Reviews Clinical Oncology.

[4]  G. Pentheroudakis,et al.  A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review , 2020, SAGE open medical case reports.

[5]  J. Pothen,et al.  A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report , 2019, Cureus.

[6]  C. Nelson,et al.  Nonbullous pemphigoid secondary to PD-1 inhibition , 2019, JAAD case reports.

[7]  P. Hwu,et al.  IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy , 2019, Cancer Immunology Research.

[8]  C. Ko,et al.  Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single‐institution retrospective analysis with stratification of reactions by toxicity and implications for management , 2019, Journal of the American Academy of Dermatology.

[9]  G. Fabbrocini,et al.  Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. , 2019, European journal of cancer.

[10]  L. Geskin,et al.  A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management , 2018, The oncologist.

[11]  L. Geskin,et al.  A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors , 2018, International journal of dermatology.

[12]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[13]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[14]  J. Radford,et al.  Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma , 2018, JAAD case reports.

[15]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Ransohoff,et al.  Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. , 2017, Clinical lymphoma, myeloma & leukemia.

[17]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[18]  L. Beck,et al.  Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  T. Nagano,et al.  Aprepitant for refractory nivolumab-induced pruritus. , 2017, Lung cancer.

[20]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Reinmuth,et al.  Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. , 2017, Cancer treatment reviews.

[22]  S. Granter,et al.  Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. , 2017, JAMA dermatology.

[23]  G. Jeudy,et al.  Anti‐PD1‐induced psoriasis: a study of 21 patients , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  Enno Schmidt,et al.  Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial , 2017, The Lancet.

[25]  Q. Ng,et al.  Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. , 2017, European journal of cancer.

[26]  S. Frega,et al.  Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab , 2017, European Journal of Dermatology.

[27]  F. Samie,et al.  Cutaneous adverse effects of the immune checkpoint inhibitors. , 2017, Current problems in cancer.

[28]  M. Garg,et al.  Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..

[29]  J. Wargo,et al.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.

[30]  R. Bergman,et al.  Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression , 2017, Clinical and experimental dermatology.

[31]  J. Messina,et al.  Epidermal programmed cell death‐ligand 1 expression in TEN associated with nivolumab therapy , 2017, Journal of cutaneous pathology.

[32]  M. Tomayko,et al.  Development of bullous pemphigoid during nivolumab therapy , 2016, JAAD case reports.

[33]  S. Gettinger,et al.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. , 2016, JAMA dermatology.

[34]  Matthieu Texier,et al.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[35]  J. Mazières,et al.  Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies , 2016, Current opinion in oncology.

[36]  P. Chia,et al.  Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). , 2016, Journal of immunotherapy.

[37]  J. Wolchok,et al.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.

[38]  J. Utikal,et al.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[39]  R. Novoa,et al.  Immunohistochemical analysis of lichenoid reactions in patients treated with anti‐PD‐L1 and anti‐PD‐1 therapy , 2016, Journal of cutaneous pathology.

[40]  L. French,et al.  Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy , 2016, Clinical Cancer Research.

[41]  K. Byth,et al.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.

[42]  J. Wolchok,et al.  Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 , 2016, Cancer Immunology Research.

[43]  A. Daud,et al.  Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. , 2015, JAMA dermatology.

[44]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[45]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  S. Bagaria,et al.  Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy , 2014, Cancer Immunology Research.

[47]  P. Fernández-Peñas,et al.  Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death–1 (anti–PD-1) Therapy With or Without Ipilimumab , 2017, The American Journal of dermatopathology.